2nd ADC Toxicity Summit

Toxicities continue to pose the most significant challenge in the progression of antibody-drug conjugates to the clinic, and with increasing companies entering into the ADC space and tackling toxicity, there is ever-increasing target and indication-competition. Considering the significant clinical setbacks witnessed in 2023, the demand to better understand the translatability of toxicities and develop more tolerable ADCs for achieving future clinical triumphs only grows stronger.

By addressing translational challenges and tackling off-target toxicities, the 2nd ADC Toxicity Summit is returning at an imperative time to allow you to prevent, predict and mitigate toxicities in order to design and develop ADCs with a wider therapeutic index and progress them to the clinic.

Join 80+ of your colleagues from Pfizer, Merck, ImmunoGen, Mersana, Daiichi Sankyo, AbbVie and more, to discuss shared challenges with ADC toxicities from in vitro all the way to the clinic. Hear from experts in toxicology and translational sciences as they disclose never-heard before toxicity data, share insights into optimal in vivo models for predictability, investigate the use of biomarkers for patient specific ADC prescription and introduce innovative strategies to transform the ADC landscape to increase therapeutic index.

Join us in uniting the leading minds in ADC toxicology, offering actionable insights to unlock the full potential of predicting and mitigating toxicities in ADC development and addressing unmet needs head-on across three days of highly focused content - Don't miss out!

URLs:
Website: https://go.evvnt.com/2381308-0?pid=10018
Tickets: https://go.evvnt.com/2381308-2?pid=10018
Brochure: https://go.evvnt.com/2381308-3?pid=10018

Prices:
FULL PACKAGE: Conference + Workshop Day - Drug Developer: USD 4197.00,
Conference Only - Drug Developer: USD 2999.00,
FULL PACKAGE: Conference + Workshop Day - Solution Provider: USD 5097.00,
Conference Only - Solution Provider: USD 3699.00

Speakers: Ali Warbington, Director, Toxicology, ImmunoGen, Arnima Bisht, Senior Director, Oxford BioTherapeutics, Christian Marsolais, Senior Vice-President and Chief Medical Officer, Theratechnologies Inc., Doo Young Jung, CEO, pinotbio, Grace Lytle, Executive Ocular Medical Director, ImmunoGen, Jacqueline Kinyamu-Akunda, Global Head of ADC Discovery and Development, Johnson and Johnson, Josée Hue-Perron, Associate Principal Scientist in Preclinical Safety, Debiopharm, Jutta Deckert, Vice President, Research and Development, Iksuda Therapeutics, Kristin Decker, Associate Director Pharmacology and Toxicology, Heidelberg Pharma, Laurie Tatalick, Consultant, Laurie Tatalick Consulting, Marini Thian, Senior Scientist, Takeda, Melissa Schutten, Senior Director, Pathology, Pfizer, Michael Oropallo, Principal Scientist, Merck and Co, Natalie Keirstead, Senior Vice President - Nonclinical Development, Mersana Therapeutics, Paul Jaminet, President, Angiex, Philip Huxley, Vice President, Oncology, Bicycle Therapeutics, Piper Treuting, Director - Translational Sciences and Pathology, Pfizer, Ronnie Yeager, Project Director, Emerging Therapeutic Platforms, Abbvie, Werner Rubas, Vice President - Preclinical Development, Sutro Biopharma, Zenta Tsuchihashi, Senior Director - Translational Science and Oncology, Daiichi Sankyo, Inc.